perpetanji					
All rights reserved. No reuse allowed without permission					

1	Incidence and Predictors of In-stent Restenosis Following
2	Intervention for Pulmonary Vein Stenosis due to Fibrosing
3	Mediastinitis
4	Running title: Contributors toward ISR for PVS-FM
5	Mengfei Jia ^{1*} , Hongling Su ^{2*} , Kaiyu Jiang ² , Aqian Wang ² , Zhaoxia Guo ² , Hai Zhu ² ,
6	Fu Zhang ² , Pan Xin ^{3#} , Yunshan Cao ^{2#}
7	[*] Mengfei Jia and Hongling Su contributed equally to this work.
8	¹ The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu
9	Provincial Hospital), Lanzhou, Gansu 730000, China;
10	² Department of Cardiology, Pulmonary Vascular Disease Center, Gansu
11	Provincial Hospital, Lanzhou, Gansu 730000, China;
12	³ Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University,
13	Shanghai 200030, China.
14	[#] Corresponding authors: Yunshan Cao, E-mail: yunshancao@126.com; Xin Pan, E-
15	mail: panxin805@163.com.
16	Funding sources: This work was supported by the National Natural Science
17	Foundation of China (82070052) and the Open Project of State Key Laboratory of
18	Respiratory Disease (SKLRD-OP-202301).
19	Acknowledgments: All individuals who contributed to this publication have been
20	included as authors.

1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21	Abstract Presentation: This abstract has been accepted for presentation at the
22	European Society of Cardiology Congress 2023 on August 26, 2023, in Amsterdam,
23	the Netherlands. It was also accepted for publication by the European Society of
24	Cardiology.
25	Trial Registry: Chinese Clinical Trials Register; No.: ChiCTR2000033153. URL:
26	http://www.chictr.org.cn
27	Disclosures: The authors declare no conflicts of interest.
28	Author contributions: Y.C. and X.P. conceptualized and designed the study. K.J.
29	and A.W. searched the literature and collected data. M.J. undertook data analysis. Z.G.
30	H.Z. and F.Z. provided clinical commentary on methods and interpretation. M.J. and
31	H.S. drafted the initial manuscript, with critical revision of the article from all authors.
32	Y.C. and X.P. reviewed the manuscript. Y.C. is responsible for the overall content as
33	guarantor.
34	Word Count Abstract: 227
35	Word Count Text: 2982

Abbreviations: Cor-PA = corresponding pulmonary artery; FLD = final lumen
diameter; FM = fibrosing mediastinitis; ISR = in-stent restenosis; LA = left atrium;
MLD = minimal lumen diameter; PA = pulmonary artery; Pd = pressure gradient;
PTPV = percutaneous transluminal pulmonary venoplasty; PV = pulmonary vein;
PVFG = pulmonary venous flow grade; PVI = pulmonary vein isolation; PVS =

pulmonary vein stenosis; PVS-FM = pulmonary vein stenosis caused by fibrosing
mediastinitis; RVD = reference vessel diameter.

43 Keywords: fibrosing Mediastinitis; in-stent restenosis; predictor; pulmonary veins;

44 stenting

45 Abstract

Background: Percutaneous transluminal pulmonary venoplasty (PTPV) is an
emerging treatment for pulmonary vein stenosis (PVS) caused by fibrosing
mediastinitis (FM). However, the incidence and predictors of in-stent restenosis (ISR)
are elusive. We sought to identify the predictors of ISR in patients with PVS caused
by extraluminal compression due to FM.

51 **Methods:** We retrospectively enrolled patients with PVS-FM who underwent PTPV 52 between July 1, 2018, and December 31, 2022. According to ISR status, patients were 53 divided into two groups: the ISR group and the non-ISR group. Baseline 54 characteristics (demographics and lesions) and procedure-related information were 55 abstracted from patient records and analyzed. Univariate and multivariate analyses 56 were performed to determine the predictors of ISR.

57 **Results**: A total of 142 stents were implanted in 134 PVs of 65 patients with PVS-FM.

58 Over a median follow-up of 6.6 (3.4-15.7) months, 61 of 134 PVs suffered from ISR.

59 Multivariate analysis demonstrated a significantly lower risk of ISR in PVs with a 60 larger reference vessel diameter (RVD) (odds ratio (OR): 0.79; 95% confidence

61 interval [CI]: 0.64 to 0.98; P=0.032), and stenosis of the corresponding pulmonary

artery (Cor-PA) independently increased the risk of restenosis (OR: 3.41; 95% CI: 62 1.31 to 8.86; P=0.012). The cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, 63 and 12-month follow-ups, respectively. 64 Conclusion: ISR is very high in PVS-FM, which is independently associated with 65 66 RVD and Cor-PA stenosis. Introduction 67 Fibrosing mediastinitis (FM) is characterized by benign proliferative fibrous tissue in 68 the mediastinum, often compressing the pulmonary artery (PA), pulmonary vein (PV), 69 bronchi, and superior vena cava, presenting with cough, dyspnea, hemoptysis, pleural 70 71 effusion, superior vena cava syndrome, pulmonary hypertension, and right heart failure.^[1] Pulmonary vein stenosis (PVS) caused by FM (PVS-FM) is a kind of typical 72 73 extraluminal compressing stenosis that is rare but fatal. Percutaneous transluminal pulmonary venoplasty (PTPV) is an emerging alternative for PVS-FM.^[2-4] 74 The first balloon angioplasty (BA) reported by Massumi et al^[5] in 1981 was 75 performed in a female patient with PVS-FM. However, early reports showed that BA 76 was unsuccessful in the treatment of PVS, including a modified BA technique.^[6,7] The 77 first report on stent venoplasty of PVS-FM was in 2001, which brought a new 78 therapeutic modality for FM.^[8] Reviewing the progress of PV interventions, in the 79 early stage, transcatheter angioplasty was mainly used to correct congenital or 80 postoperative PVS in children.^[9] Since the report of PVS after pulmonary vein 81 82 isolation (PVI) in 1998, catheter-based intervention has become increasingly common

in the treatment of PVS caused by PVI (PVS-PVI) during the next 20 years.^[10]
Nevertheless, detailed information is scarce about interventional treatment for PVSFM, including hemodynamic changes, procedure-related complications,
comprehensive follow-up data, incidence, and predictors of in-stent restenosis
(ISR).^[11]

The pathogenesis of PVS-FM is different from that of PVS-PVI and congenital 88 PVS. PVS-FM is attributed to extraluminal proliferative fibrous tissue 89 compression,^[12] while other PVS are attributed to intimal hyperplasia.^[13,14] Hence, 90 even though PTPV has been successfully used in PVS-PVI, PTPV in PVS-FM might 91 92 be different. Our preliminary data showed that patients with PVS-FM who underwent interventions, both in terms of hemodynamics and exercise capacity, had clinical 93 94 improvement but a high prevalence of restenosis during a very short-term followup.^[15] Therefore, identifying the clinical and procedural factors associated with ISR is 95 critical to guide intervention and optimize postintervention surveillance strategies. 96 Against this background, we sought to identify the predictors associated with ISR 97 following PVS-FM intervention. 98

99 Methods

100 Study population

From July 1, 2018, to December 31, 2022, we identified 144 patients with FM according to history, symptoms, signs, and findings in enhanced computed tomography (CT) with contrast in our center. Patients with PVS caused by tumors and

other diseases were excluded. Patients were followed from PVS-FM diagnosis until
the last follow-up or until May 2023 if receiving ongoing care. Patients were followed
at set intervals with repeat CT imaging at 1-3, 3-6, 6-12, and 24 months after the
intervention.

108 Data collection

109 Patient clinical data at baseline and follow-up periods were collected. If a patient with PVS-FM was analyzed as part of the ISR cohort and the patient also had normal 110 veins, the patient might have had veins analyzed in 2 different cohorts. The 111 112 procedure-related parameters collected included minimal lumen diameter (MLD). 113 lesion length, and reference vessel diameter (RVD) (taken as the mean diameter of the 114 normal-appearing proximal and distal segment; if the PV diameter at both ends of the 115 stenotic site was greatly different, the diameter of the distal PV served as the reference 116 diameter). Furthermore, the maximal balloon diameter (using the actual measured maximal balloon size), maximal balloon inflation pressure, stent diameter, stent 117 length, maximal stent inflation pressure, final lumen diameter (FLD), balloon-to-118 vessel ratio (calculated as the largest diameter of the inflated balloon divided by 119 120 RVD), vessel-to-stent ratio (calculated as the FLD divided by stent diameter), and 121 diameter stenosis (%) (calculated as [1-(MLD/RVD)]×100%) were also included. In addition, PA narrowing in series with stenotic PV, pleural effusion, and postoperative 122 123 anticoagulants was collected. The pulmonary venous flow grade (PVFG) was assigned using grades 0-3.^[15] 124

125 Outcomes

126	The primary endpoint of the study was the incidence of ISR following PTPV or
127	pulmonary angiography during the follow-up period, and the secondary endpoints
128	were the World Health Organization functional class (WHO-FC) and 6-minute
129	walking distance (6MWD). We also analyzed the demographic, clinical and
130	procedural variables associated with ISR.

131 Second, we sought to understand the outcomes of patients with PVS-FM who132 underwent pulmonary vein intervention only.

ISR was defined as stenosis >50% of the vessel size as confirmed by repeated
angiography or an increase in pressure gradient (Pd) (≥5 mmHg) across the stenotic

135 site compared to the last measurement.

136 Research ethics and patient consent

137 The ethics committee of Gansu Provincial Hospital reviewed and approved the study

138 protocol (2022-302) on 25, August 2022 as well as granted exemption from obtaining

139 informed consent from patients.

140 **Data availability**

- 141 Anonymized data used and/or analyzed during the current study are available from the
- 142 corresponding author upon reasonable request from any qualified investigator for the143 sole purpose of the study.

144 Statistical analysis

perpetuity. All rights reserved. No reuse allowed without permission.

145 Categorical data are expressed as counts and proportions (%). Continuous data are reported as the mean \pm SD or as the median (interquartile range). The Kolmogorov-146 147 Smirnov test was used to determine the normality of the data distribution. For continuous variables, t tests or Wilcoxon rank sum tests were used as appropriate. For 148 categorical variables, χ^2 tests or Fisher exact tests were used. A binary logistic 149 150 analysis was used to construct an optimal model in multiple variables analysis. Receiver operating characteristic (ROC) analyses were used to determine the 151 predictive power of variables for ISR. A 95% confidence interval (CI) is provided for 152 153 all estimates. A P value<0.05 was considered significant. The Kaplan-Meier method was used to estimate and plot the time curves for the appearance of restenosis in the 154 initial intervention vessels, and the log-rank test was used to compare restenosis 155 156 between the different sizes of RVD. Statistical analysis was performed using SPSS version 25.0 (SPSS, Chicago, Illinois), and figures were plotted by GraphPad Prism 157 software v.8.0 (GraphPad Software, San Diego, California USA). 158

159 **Results**

160 **Baseline characteristics**

The study flowchart is shown in **Figure 1**. Of 144 patients with FM during the study period, 43 patients who did not undergo PV intervention, 2 patients with unsuccessful PV intervention, and 7 patients who underwent balloon pulmonary venoplasty (BPV) alone were excluded. A total of 92 patients successfully underwent percutaneous transluminal stent venoplasty. Of them, twenty-five (27.2%) patients were lost to

166 follow-up, 2 (2.2%) had no imaging data at follow-up, and 65 patients (70.7%) with 142 stents implanted in 134 lesioned PVs during 72 sessions underwent CT and/or 167 168 selective pulmonary venographic surveillance at a median of 6.6 (3.4-15.7) months of follow-up. Of the 65 patients ultimately included in the analysis, 2 veins were 169 170 implanted with stents directly without ballooning, 8 veins were implanted with 2 171 overlapping stents due to long-segment lesions, and 126 veins were stented after initial balloon venoplasty failed to improve the Pd across the stenotic site. The 172 baseline characteristics are shown in Table 1, and the procedural and lesion 173 174 characteristics are shown in Table 2.

175 Incidence of in-stent restenosis (ISR)

At a median follow-up of 6.6 (3.4-15.7) months, ISR was found in 61 of 134 treated
veins. The cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, and 12-month
follow-ups, respectively (Figure 2).

179 Univariate analysis

Patients with and without ISR had similar ages, sex distribution, body mass index, and medical histories, including chronic obstructive pulmonary disease, diabetes mellitus (DM), tuberculosis, etc. There were also no significant differences in the hemodynamic and laboratory parameters between the two groups. The analysis of clinical factors failed to identify any factors significantly correlated with ISR. Among procedure-related factors, MLD, RVD, FLD, stent diameter, stent length, stent-tovessel ratio, and stenosis of the corresponding pulmonary artery (Cor-PA) were

187 associated with ISR (**Table 3**).

188 Multivariate analysis

189 To guarantee that there was no multicollinearity among the variables, the appropriate variables were selected by calculating the tolerance and variance inflation factor 190 191 (VIF). Then, a covariance diagnosis on the indicators that were significant in the 192 results of univariate analysis and on the variables that might be clinically significant was performed. The variables with tolerances less than 0.1 and a VIF greater than 10 193 were excluded, while the remaining variables were analyzed through multivariate 194 195 analysis. Procedure-related parameters that were independently associated with ISR included the RVD and the stenosis of Cor-PA (central illustration). For ISR, RVD 196 197 was associated with an adjusted OR of 0.79 (95% CI, 0.64 to 0.98, P=0.032), while 198 the stenosis of Cor-PA was associated with an adjusted OR of 3.41 (95% CI, 1.31 to 8.86, P=0.012). The results of the ROC analysis for procedure-related variables for 199 ISR are depicted in Figure 3. RVD>8.4 mm could be used as the cutoff point to 200 predict ISR, and its sensitivity and specificity were 0.84 and 0.38, respectively. The 201 subgroup of vessels with a reference diameter >8.4 mm had a significantly lower risk 202 of ISR than the subgroup with a reference diameter <8.40 mm (Figure 3D). 203 Meanwhile, the sensitivity and specificity of Cor-PA stenosis were 0.89 and 0.69, 204 respectively. When the positive and negative influencing factors were combined, the 205 sensitivity and specificity were 0.77 and 0.55, respectively. Hence, we obtained the 206

207 regression equation of related variables and restenosis: Logit (*P*)=0.614208 0.236×RVD+1.226×Cor-PA stenosis (Cor-PA stenosis =1 if present, 0 absent).

209 **Procedural complications**

In the analysis of 72 sessions performed in 65 patients, there were 13 episodes of 210 211 chest tightness (18%) and 14 episodes of cough (19%), which were the most common 212 during the intervention (Supplemental Table 1). Mild hemoptysis and transient cardiac arrest/bradycardia occurred in 7% and 4% of sessions, respectively, with no 213 requirement for additional intervention. There were 2 (3%) patients experiencing PV 214 dissection/perforation who underwent balloon occlusion with low inflation pressure 215 216 and recovered without any hemodynamic insults. One patient suffered from suspected acute pulmonary edema with acute onset of dyspnea and elevated left atrial pressure 217 218 after stent implantation, high flow oxygen, and diuretics were administered, and these symptoms were relieved soon after. There were no cases of peri-procedure death or 219 major hemoptysis occurred. 220

221 Immediate and short-term efficacy

The MLD, Pd, and PVFG in the recruited patients were evaluated pre- and postintervention and drastically improved after the intervention. The MLD increased from 2.2 (1.9, 2.9) mm to 6.6 (5.6, 8.1) mm, and PVFG and Pd were significantly improved (P<0.001 for all) (**Figure 4A-C**). Additionally, due to 17 patients undergoing PA intervention at the same time or later, the short-term efficacy of the remaining 43 (66.2%) patients with only PV intervention at follow-up was analyzed.

228 The median follow-up was 5.0 (3.1-11.2) months. Among the 43 patients, 23 underwent right heart catheterization during the follow-up. Comparisons of the 229 baseline and follow-up data in patients with PV intervention are shown in Table 4. 230 The pleural effusion decreased from 35 (81.3%) to 20 (46.5%) (3 of which were new 231 pleural effusions) (P<0.005) during the follow-up. However, there was no 232 improvement in the postoperative WHO-FC or 6MWD (P>0.05) (Figure 4D-F). The 233 mean PAP had a significant improvement (P=0.016), and there was an increase in left 234 atrial size (P=0.439) but with no statistical significance. 235

Discussion 236

243

In this study, we focused on the incidence and predictors of ISR in PVS-FM. The 237 salient findings are as follows: 1) the incidence of ISR following stent implantation of 238 239 PVS-FM is as high as 6.3%, 21.4%, and 39.2% at 3-, 6-, and 12-month follow-ups, respectively; 2) RVD is an independent factor for ISR, and the stenosis of the Cor-PA 240

largely affects the occurrence of restenosis. 241

242 In-stent restenosis and associated factors in PV intervention of PVS-FM

Previously, Albers et al.^[4] reported a restenosis rate of 7/16 (44%) patients with PVS-FM during a median 115-month follow-up. Similarly, the Mayo Clinic experience 244 described a restenosis rate of up to 4/8 (50%) patients with PVS-FM after the 245 246 intervention.^[3] However, the incidence of restenosis in the above studies might not be accurate and underestimated for the following reasons: 1) the sample size of the above 247 studies was small; 2) three patients were detected by routine CT angiography without 248

associated symptoms, and 4 patients had symptomatic restenosis in the study by 249 Albers et al.^[4] The overall median time of 115 months was the time to the symptom of 250 restenosis. 3) In the study from the Mayo Clinic, 2 of the remaining 4 patients died 251 shortly after the procedure.^[3] In our study, CT angiography was routinely performed 252 to surveil ISR in 134 PVs of 65 patients with PVS-FM. A total of 61/134 (45.5%) PVs 253 and 42/65 (64.6%) patients had ISR during a median of 6.6 months of follow-up. The 254 cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, and 12-month follow-ups, 255 respectively. Accordingly, this study confirms the high ISR rate with more detailed 256 and accurate information in a larger cohort of PVS-FM patients. A high restenosis rate 257 was also reported in PVS with other etiologies, including PVI. In PVI-PVS, the rate 258 of restenosis is between 19%-39% after a median follow-up period of 6.0-55.2 259 months.^[16-20] Recently, a meta-analysis depicted that the total restenosis rate was 54% 260 in BA and 22.3% in stenting of PVS with different etiologies during a median follow-261 up time of 13-69 months.^[21] Hence, ISR in PVS-FM is higher than that in PVI-PVS. 262 Furthermore, the factors associated with ISR were analyzed by a multiple variables 263 logistic model in this study. We found that RVD and Cor-PA stenosis were 264 independent predictors of ISR following PV intervention in patients with PVS-FM. 265 Previous studies have shown that stent size is associated with restenosis in PVI-PVS. 266 Prieto et al.^[20] reported that a stent diameter <10 mm may increase the risk of 267 restenosis. Furthermore, a stent size ≥ 7 mm was associated with lower restenosis, 268 which was described by Balasubramanian et al.^[22] Additionally, some scholars have 269

recommended that a stent diameter >8 mm may serve as the first choice of treatment 270 for PV intervention.^[16] Our findings are consistent with previous results to some 271 272 extent; however, this result is more rational because the choice of stent size is based on the RVD, which was speculated by Prieto et al.^[20] who suggested that smaller RVD 273 could increase the rate of restenosis. Meanwhile, the explanation for the higher ISR in 274 PVS-FM than in PVI-PVS is as follows. The involved PVs are often different in 275 diameter. PVI-PVS is always located at the ostia of PV with a larger caliber, while 276 PVS-FM is at the proximal 1st tributary of PV with a smaller caliber. In addition, 277 different pathogeneses could be another attribute. PVI-PVS is intraluminal intimal 278 279 hyperplasia by physicochemical injury, while PVS-FM is extraluminal by proliferative fibrous tissue compression. PVS-FM might be more easily injured by 280 balloon or stent inflation than PVI-PVS. As expected, Cor-PA stenosis is an exclusive 281 factor associated with ISR, which should be given more attention in PV intervention. 282 Wang et al^[12] previously classified FM into 3 types: only the artery involved, only the 283 vein is compressed, and there is both artery and vein narrowing, which should be a 284 mandatory evaluation for an interventional strategy of patients with FM. Overall, the 285 ISR following PV intervention is significantly higher than that following PA 286 intervention, regardless of the etiology of PVS, which may be attributed to the lower 287 pressure in the venous system.^[19] A mismatch between the stent and the vessel might 288 increase the occurrence of restenosis.^[23] Additionally, it was shown that PVS severity 289 correlated with the severity of the corresponding lung segment in PVS in children.^[24] 290

Either over- or underinflation of the balloon or stent may affect restenosis, which has 291 been demonstrated in coronary artery intervention.^[25-27] Earlier studies documented 292 some factors of restenosis after percutaneous coronary intervention, including vessel 293 size, maximal balloon pressure, stent type, final diameter stenosis, DM, etc.^[28] 294 Endoluminal imaging techniques (e.g., optical coherence tomography, OCT; 295 intravenous ultrasound, IVUS) with existing imaging techniques (e.g., CT 296 angiography, pulmonary venography) may promote standardized management by 297 allowing for intraoperative guidance of stent deployment and postoperative 298 assessment of luminal changes (e.g., thrombosis, intimal hyperplasia) in coronary 299 artery intervention;^[29] however, they are limited in PV intervention. Drug-eluting 300 stents have been widely used in coronary artery disease to prevent restenosis.^[23] 301 302 Moreover, Masaki and his team revealed that rapamycin-eluting films could suppress pulmonary vein obstruction progression,^[30] which is promising for ISR in PV 303 intervention. In other words, further study is necessary. 304

305 Safety and efficacy of PV intervention of the PVS-FM

A previous study in 8 patients with PVS-FM demonstrated that the incidence of periprocedure complications and mortality are as high as 3/8 (37.5%) and 3/8 (37.5%), respectively.^[3] Another study showed that overall procedure-related complications in patients with FM, including PA, PV, and SVC intervention, were 15/58 (26%) minor and 6/58 (10%) severe.^[4] In the present large cohort study, we found that some patients had a cough (19%), chest tightness (18%) and other discomfort (18%),

312 including palpitations, dizziness, nausea, etc. No major hemoptysis or periproced death occurred. The incidence and severity of complications in this study are different 313 314 from the previous description, which could be attributed to concomitant conditions, inflation pressure, location of PV lesion, and patient status. 315 In this study, there were immediate improvements in PV caliber, Pd across lesions, 316 317 and PVFG after the intervention compared with before the intervention, which further supported the findings in previous small sample-sized studies.^[3,4] The PAP evaluated 318 by right heart catheterization decreased in the follow-up period. Notably, the lack of 319 320 improvement in exercise capacity (6MWD, WHO-FC) but having a trend of increase may be attributed to the fact that some of the patients had a recurrence of symptoms 321 or needed further intervention (nearly 50%) during follow-up. On the other hand, 322 323 remaining PA stenosis may have a negative influence on the overall efficacy. Hence, further long-term follow-up is needed to analyze the efficacy of PV intervention with 324 the PVS-FM. 325

326 Limitations

There are some limitations in this study. First, most ISRs were evaluated by CT venography, which might underestimate or overestimate the degree of restenosis. Second, the sample size was small, and the data were from a single center, which might unavoidably have some bias, even though it was the largest cohort study to date. Third, the follow-up data were not complete, and some patients were lost to

- 332 follow-up. Finally, no long-term efficacy was followed up because most patients
- 333 underwent subsequent PA intervention.

334 Conclusions

- 335 The ISR is very high after the initial intervention of PVS-FM, which is independently
- associated with RVD and the stenosis of Cor-PA.

352 References

- 353 1. Rossi SE, McAdams HP, Rosado-de-Christenson ML, Franks TJ, Galvin JR.
- 354 Fibrosing mediastinitis. Radiographics 2001;21(3):737-571.
- doi:org/10.1148/radiographics.21.3.g01ma17737.
- 2. Fender EA, Widmer RJ, Knavel Koepsel EM, Welby JP, Kern R, Peikert T, et al.
- 357 Catheter based treatments for fibrosing mediastinitis. Catheter Cardiovasc Interv
- 358 2019;94(6):878-8851. doi:org/10.1002/ccd.28152.
- 359 3. Ponamgi SP, DeSimone CV, Lenz CJ, Coylewright M, Asirvatham SJ, Holmes DR,
- 360 et al. Catheter-based intervention for pulmonary vein stenosis due to fibrosing
- 361 mediastinitis: The Mayo Clinic experience. Int J Cardiol Heart Vasc 2015;8:103-1071.
- doi:org/10.1016/j.ijcha.2015.06.005.
- 363 4. Albers EL, Pugh ME, Hill KD, Wang L, Loyd JE, Doyle TP. Percutaneous vascular
- 364 stent implantation as treatment for central vascular obstruction due to fibrosing
- 365 mediastinitis. Circulation 2011;123(13):1391-91.
- 366 doi:org/10.1161/CIRCULATIONAHA.110.949180.
- 367 5. Massumi A, Woods L, Mullins CE, Nasser WK, Hall RJ. Pulmonary venous
- dilatation in pulmonary veno-occlusive disease. Am J Cardiol 1981;48(3):585-91.
- 369 doi:org/10.1016/0002-9149(81)90092-8.
- 370 6. Driscoll DJ, Hesslein PS, Mullins CE. Congenital stenosis of individual pulmonary
- 371 veins: clinical spectrum and unsuccessful treatment by transvenous balloon dilation.
- 372 Am J Cardiol 1982;49(7):1767-721. doi:org/10.1016/0002-9149(82)90257-0.
- 373 7. Lock JE, Bass JL, Castaneda-Zuniga W, Fuhrman BP, Rashkind WJ, Lucas RV, Jr.

- 374 Dilation angioplasty of congenital or operative narrowings of venous channels.
- 375 Circulation 1984;70(3):457-64l. doi:org/10.1161/01.cir.70.3.457.
- 8. Doyle TP, Loyd JE, Robbins IM. Percutaneous pulmonary artery and vein stenting:
- a novel treatment for mediastinal fibrosis. Am J Respir Crit Care Med
- 378 2001;164(4):657-601. doi:org/10.1164/ajrccm.164.4.2012132.
- 379 9. Mendelsohn AM, Bove EL, Lupinetti FM, Crowley DC, Lloyd TR, Fedderly RT, et
- al. Intraoperative and percutaneous stenting of congenital pulmonary artery and vein
- 381 stenosis. Circulation 1993;88(5 Pt 2):II210-71.
- 382 10. Robbins IM, Colvin EV, Doyle TP, Kemp WE, Loyd JE, McMahon WS, et al.
- 383 Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Circulation
- 384 1998;98(17):1769-751. doi:org/10.1161/01.cir.98.17.1769.
- 385 11. Duan Y, Zhou X, Su H, Jiang K, Wu W, Pan X, et al. Balloon angioplasty or stent
- implantation for pulmonary vein stenosis caused by fibrosing mediastinitis: a
- 387 systematic review. Cardiovasc Diagn Ther 2019;9(5):520-5281.
- 388 doi:org/10.21037/cdt.2019.09.14.
- 389 12. Wang A, Su H, Duan Y, Jiang K, Li Y, Deng M, et al. Pulmonary Hypertension
- 390 Caused by Fibrosing Mediastinitis. JACC: Asia 2022;2(3_Part_1):218-2341.
- 391 doi:org/doi:10.1016/j.jacasi.2021.11.016.
- 392 13. Nasr VG, Callahan R, Wichner Z, Odegard KC, DiNardo JA. Intraluminal
- 393 Pulmonary Vein Stenosis in Children: A "New" Lesion. Anesth Analg 2019;129(1):27-
- 394 40l. doi:org/10.1213/ANE.00000000003924.

- 395 14. Suntharos P, Worley SE, Liu W, Siperstein M, Prieto LR. Long-term outcome of
- 396 percutaneous intervention for pulmonary vein stenosis after pulmonary vein isolation
- 397 procedure. Catheter Cardiovasc Interv 2020;95(3):389-3971.
- 398 doi:org/10.1002/ccd.28628.
- 399 15. Duan YC, Su HL, Wei R, Jiang KY, Wang AQ, Yang YH, et al. Short-term
- 400 efficacy and perioperative safety of catheter-based intervention for pulmonary vein
- 401 stenosis caused by fibrosing mediastinitis. Zhonghua Xin Xue Guan Bing Za Zhi
- 402 2022;50(1):55-611. doi:org/10.3760/cma.j.cn112148-20210507-00398.
- 403 16. Schoene K, Arya A, Jahnke C, Paetsch I, Nedios S, Hilbert S, et al. Acquired
- 404 Pulmonary Vein Stenosis After Radiofrequency Ablation for Atrial Fibrillation:
- 405 Single-Center Experience in Catheter Interventional Treatment. JACC Cardiovasc
- 406 Interv 2018;11(16):1626-16321. doi:org/10.1016/j.jcin.2018.05.016.
- 407 17. Widmer RJ, Fender EA, Hodge DO, Monahan KH, Peterson LA, Holmes DR, Jr.,
- 408 et al. Contributors Toward Pulmonary Vein Restenosis Following Successful
- 409 Intervention. JACC Clin Electrophysiol 2018;4(4):547-5521.
- 410 doi:org/10.1016/j.jacep.2017.10.001.
- 411 18. Fender EA, Widmer RJ, Hodge DO, Cooper GM, Monahan KH, Peterson LA, et
- 412 al. Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation:
- 413 Presentation, Management, and Clinical Outcomes. Circulation 2016;134(23):1812-
- 414 18211. doi:org/10.1161/CIRCULATIONAHA.116.021949.
- 415 19. Fink T, Schluter M, Heeger CH, Lemes C, Lin T, Maurer T, et al. Pulmonary vein

- 416 stenosis or occlusion after catheter ablation of atrial fibrillation: long-term comparison
- 417 of drug-eluting versus large bare metal stents. Europace 2018;20(10):e148-e1551.
- 418 doi:org/10.1093/europace/eux291.
- 419 20. Prieto LR, Schoenhagen P, Arruda MJ, Natale A, Worley SE. Comparison of stent
- 420 versus balloon angioplasty for pulmonary vein stenosis complicating pulmonary vein
- 421 isolation. J Cardiovasc Electrophysiol 2008;19(7):673-81. doi:org/10.1111/j.1540-
- 422 8167.2008.01110.x.
- 423 21. Almakadma AH, Sarma D, Hassett L, Miranda W, Alkhouli M, Reeder GS, et al.
- 424 Pulmonary Vein Stenosis-Balloon Angioplasty Versus Stenting: A Systematic Review
- 425 and Meta-Analysis. JACC Clin Electrophysiol 2022;8(10):1323-13331.
- 426 doi:org/10.1016/j.jacep.2022.08.008.
- 427 22. Balasubramanian S, Marshall AC, Gauvreau K, Peng LF, Nugent AW, Lock JE, et
- 428 al. Outcomes after stent implantation for the treatment of congenital and postoperative
- 429 pulmonary vein stenosis in children. Circ Cardiovasc Interv 2012;5(1):109-171.
- 430 doi:org/10.1161/CIRCINTERVENTIONS.111.964189.
- 431 23. Prieto LR. The State of the Art in Pulmonary Vein Stenosis -Diagnosis &
- 432 Treatment. J Atr Fibrillation 2010;2(4):2281. doi:org/10.4022/jafib.228.
- 433 24. Sena L, Callahan R, Sleeper LA, Beroukhim RS. Prognostic Significance of
- 434 Computed Tomography Findings in Pulmonary Vein Stenosis. Children (Basel)
- 435 2021;8(5)doi:org/10.3390/children8050402.
- 436 25. Aziz S, Morris JL, Perry RA, Stables RH. Stent expansion: a combination of

- 437 delivery balloon underexpansion and acute stent recoil reduces predicted stent
- 438 diameter irrespective of reference vessel size. Heart 2007;93(12):1562-61.
- 439 doi:org/10.1136/hrt.2006.107052.
- 440 26. Shlofmitz E, Iantorno M, Waksman R. Restenosis of Drug-Eluting Stents: A New
- 441 Classification System Based on Disease Mechanism to Guide Treatment and State-of-
- the-Art Review. Circ Cardiovasc Interv 2019;12(8):e0070231.
- 443 doi:org/10.1161/CIRCINTERVENTIONS.118.007023.
- 444 27. Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-
- stent restenosis. EuroIntervention 2022;18(2):e103-e1231. doi:org/10.4244/EIJ-D-21-
- 446 01034.
- 447 28. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and
- 448 predictors of restenosis after coronary stenting in 10 004 patients with surveillance
- 449 angiography. Heart 2014;100(2):153-91. doi:org/10.1136/heartjnl-2013-304933.
- 450 29. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al.
- 451 Angiographic patterns of in-stent restenosis: classification and implications for long-
- 452 term outcome. Circulation 1999;100(18):1872-81. doi:org/10.1161/01.cir.100.18.1872.
- 453 30. Masaki N, Adachi O, Katahira S, Saiki Y, Horii A, Kawamoto S, et al. Progression
- 454 of vascular remodeling in pulmonary vein obstruction. J Thorac Cardiovasc Surg
- 455 2020;160(3):777-790 e51. doi:org/10.1016/j.jtcvs.2020.01.098.

456

457

462 Table 1 Baseline characteristics

	Total (N=65)	ISR (n=42)	Non-ISR (n=23)	P Value
Demographics				
Age, years	66.0 (60.0, 70.0)	64.5 (59.8, 69.3)	67.0 (60.0, 72.0)	0.38
Body mass index, kg/m ² (N=64)	22.4 ± 3.6	22.2 ± 3.5	22.7 ± 3.7	0.53
Female	29 (44.6)	20 (47.6)	9 (39.1)	0.51
Duration of symptoms, months	37.0 (24.0, 72.0)	38.0 (24.0, 72.0)	36.0 (14.0, 96.0)	0.83
Clinical presentation				
Dyspnea	61 (93.8)	38 (90.5)	23 (100.0)	0.29
Cough	20 (30.8)	15 (35.7)	5 (21.7)	0.24
Hemoptysis	4 (6.2)	4 (9.5)	0 (0.0)	0.29
Chest distress	40 (61.5)	22 (52.4)	18 (78.3)	0.040
Palpitations	3 (4.6)	2 (4.8)	1 (4.3)	1.00
Edema of lower limbs	17 (26.2)	12 (28.6)	5 (21.7)	0.55
Pleural effusion	49 (75.4)	32 (76.2)	17 (73.9)	0.84
Comorbidity				
Hypertension	21 (32.3)	14 (33.3)	7 (30.4)	0.81
Diabetes mellitus	14 (21.5)	7 (16.7)	7 (30.4)	0.22
COPD	48 (73.8)	29 (69.0)	19 (82.6)	0.23
		24		

Atelectasis	42 (64.6)	29 (69.0)	13 (56.5)	0.31
Tuberculosis	39 (60.0)	26 (61.9)	13 (56.5)	0.67
Hemodynamics (n=64)				
SaO ₂ , %	89.0 (87.3, 92.0)	89.0 (87.0, 92.0) (n=41)	90.0 (88.0, 91.0)	0.83
mRAP, mmHg	3.0 (2.0, 5.0)	3.0 (2.0, 4.5) (n=41)	5.0 (2.0, 7.0)	0.067
sPAP, mmHg	70.5 (54.0, 80.8)	71.0 (53.5, 81.0) (n=41)	68.0 (54.0, 78.0)	0.70
dPAP, mmHg	27.0 (22.0, 33.0)	27.0 (22.0, 33.0) (n=41)	27.0 (20.0, 34.0)	0.80
mPAP, mmHg	39.5 (33.0, 50.0)	40.0 (33.0, 49.5) (n=41)	39.0 (30.0, 53.0)	0.88
PAWP, mmHg (n=63)	7.0 (6.0, 9.0)	7.0 (6.0, 9.0) (n=40)	7.0 (6.0, 7.0)	0.97
PVR, WU	6.3 (5.3, 9.9)	6.3 (5.2, 9.6) (n=41)	6.8 (5.5, 10.0)	0.48
CO, L/min	4.6 (3.8, 5.4)	4.8 (3.9, 5.5) (n=41)	4.4 (3.7, 5.3)	0.34
CI, L/min/m ²	2.8 ± 0.6	$3.0 \pm 0.7 (n=41)$	2.8 ± 0.6	0.23
SvO ₂ , %	62.9 ± 9.0	63.6 ± 9.1 (n=41)	61.7 ± 9.0	0.52
Echocardiographic				
LA size, mm	32.4 ± 5.0	32.4 ± 4.9	32.3 ± 5.2	0.94
TAPSE, mm (n=50)	19.2 ± 4.6	$19.7 \pm 4.0 \ (n=33)$	$18.2 \pm 5.5 \ (n=17)$	0.30
RAA, end-systolic, cm^2 (n=42)	16.5 (14.0, 20.6)	15.8 (14.0, 22.5) (n=27)	17.5 (14.3, 20.4) (n=15)	0.66
RVA, end-diastolic, cm ² (n=42)	24.4 ± 9.2	$23.5 \pm 9.0 \ (n=27)$	$26.0 \pm 9.7 (n=15)$	0.41
Exercise capacity				

WHO-FC, I/II/III/IV	0/25/32/8	0/17/19/6	0/8/13/2	0.64
6MWD, m (n=42)	306.4 ± 97.8	$287.6 \pm 100.1 \ (n=27)$	$340.2 \pm 86.6 \text{ (n=15)}$	0.16
Laboratory values				
NT-proBNP, pg/ml	732.6 (163.5, 1568.5)	714.0 (128.3, 1374.3)	732.6 (203.0, 2678.0)	0.88
NLR (n=62)	4.7 (3.8, 6.8)	4.6 (3.8, 5.8) (n=41)	5.2 (3.3, 8.9) (n=21)	0.48
CRP, mg/L (n=59)	5.8 (1.7, 14.1)	6.3 (1.7, 16.9) (n=40)	5.6 (1.7, 9.4) (n=19)	0.75
D-Dimer, ug/ml (n=58)	1.0 (0.6, 1.5)	1.0 (0.7, 1.5) (n=36)	0.9 (0.3, 1.4) (n=22)	0.22
With PAS	63 (96.9)	41 (97.6)	22 (95.7)	1.00

Values are mean \pm SD, n (%), or M (Q1, Q3). 6MWD = 6-minute walking distance; CI = cardiac index, CO = cardiac output; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; dPAP = diastolic pulmonary artery pressure; ISR = in stent restenosis; LA = left atrial; mPAP = mean pulmonary artery pressure; NLR = Neutrophil-to-Lymphocyte ratio; NT-proBNP = N-terminal pro-brain natriuretic peptide; PAS = pulmonary artery stenosis; PAWP = pulmonary artery wedge pressure; PVR = pulmonary vascular resistance; RA = right atrial; mRAP = mean right atrial pressure; RV = right ventricle; SaO₂ = arterial oxygen saturation; sPAP = systolic pulmonary artery pressure; SvO₂ = mixed venous oxygen saturation; TAPSE = tricuspid annual plane systolic excursion; WHO-FC = World Health Organization functional class.

469

470

- 471
- 472
- 473

474

476	Table 2 Lesion	characteristics	and	procedural-rel	ated	information
-----	----------------	-----------------	-----	----------------	------	-------------

	Total (N=134)	ISR (n=61)	Non-ISR (n=73)	P Value
The lesion distribution, n (%)				0.21
LSPV	54 (40.3)	29 (47.5)	25 (34.2)	
LIPV	35 (26.1)	14 (23.0)	21 (28.8)	
RSPV	38 (28.4)	17 (27.9)	21 (28.8)	
RIPV	7 (5.2)	1 (1.6)	6 (8.2)	
Cor-PA stenosis	104 (77.6)	54 (88.5)	50 (68.5)	0.006
Stenosis severity of the Cor-PA				0.004
Normal	30 (22.4)	7 (11.5)	23 (31.5)	
Mild	36 (26.9)	13 (21.3)	23 (31.5)	
Moderate	23 (17.2)	14 (23.0)	9 (12.3)	
Severe	45 (33.6)	27 (44.3)	18 (24.7)	
MLD, mm	2.2 (1.9, 2.9)	2.1 (1.4, 2.8)	2.4 (2.1, 3.3)	0.003
RVD, mm	7.1 (6.3, 8.6)	7.0 (6.1, 8.2)	7.6 (6.6, 9.6)	0.019
Lesion length, mm (N=113)	20.1 (15.6, 25.1)	18.5 (15.2, 24.7)	20.8 (16.2, 26.3)	0.35
Diameter stenosis, %	68.1 (60.2, 75.3)	69.7 (62.1, 79.0)	67.1 (59.6, 73.9)	0.080
FLD, mm	6.6 (5.6, 8.1)	6.4 (5.4, 7.4)	7.0 (5.8, 9.0)	0.030
		27		

FLD/RVD	0.9 (0.8. 1.0)	0.9 (0.8. 1.0)	0.9 (0.8. 1.0)	0.78
Maximal balloon diameter, mm (N=132)	7.0 (5.0, 7.0)	6.0 (5.0, 7.0) (n=59)	7.0 (5.0, 8.0)	0.18
Maximal balloon length, mm (N=132)	20.0 (20.0, 20.0)	20.0 (20.0, 20.0) (n=59)	20.0 (20.0, 20.0)	0.94
Maximal balloon pressure, atm (N=129)	6.0 (6.0, 10.0)	6.0 (6.0, 10.0) (n=58)	6.0 (6.0, 8.0) (n=71)	0.13
Balloon-to-vessel ratio (N=132)	0.8 (0.8, 1.0)	0.9 (0.8, 1.0)	0.8 (0.7, 0.9)	0.006
Stent diameter, mm	7.0 (7.0, 9.0)	7.0 (6.0, 8.0)	7.0 (7.0, 9.0)	0.040
Stent length, mm	19.0 (19.0, 25.0)	19.0 (18.0, 25.0)	20.0 (19.0, 26.0)	0.035
Maximal stent pressure, atm (N=131)	10.0 (10.0, 12.0)	10.0 (10.0, 12.0) (n=59)	10.0 (10.0, 12.0) (n=72)	0.22
Stent-to-vessel ratio	1.0 (1.0, 1.0)	1.0 (1.0, 1.1)	1.0 (1.0, 1.0)	0.023
FLD/Stent	0.9 (0.8, 1.0)	0.9 (0.8, 1.0)	1.0 (0.9, 1.0)	0.069
Overlapping stents, n (%)	8 (6.0)	3 (4.9)	5 (6.8)	0.73
PVFG, 0/1/2/3 (N=133)				
Preoperative	10/41/82/0	6/21/34/0	4/20/48/0	0.38
Postoperative	0/0/0/133	0/0/0/61	0/0/0/72	1.00
Pressure gradient, mmHg				
Pd-pre (N=126)	24.0 (17.8, 30.0)	24.0 (18.3, 29.8) (n=56)	25.0 (16.8, 30.0) (n=70)	0.44
Pd-post (N=128)	0.0 (0.0, 3.0)	0.0 (0.0, 1.8) (n=56)	0.0 (0.0, 3.0) (n=72)	0.34

477 Values are mean ± SD, n (%), or M (Q1, Q3). Cor-PA = corresponding pulmonary artery; DS (%) = percentage diameter stenosis; FLD = final
478 lumen diameter; ISR = in-stent restenosis; LIPV = left inferior pulmonary vein; LSPV = left supper pulmonary vein; MLD = minimal lumen

diameter; PA = pulmonary artery; PVFG = pulmonary venous flow grade; RIPV = right inferior pulmonary vein; RSPV = right supper
pulmonary vein; RVD = reference vessel diameter.

481

482 Table 3 Per-vessel univariate and multivariate analysis associated with in-stent restenosis

	Univariate analysis		Multivariate analysis	
	OR (95% CI)	P Value	OR (95% CI)	P Value
<i>The lesion distribution, n (%)</i>				
LSPV	1 (Ref)			
LIPV	0.58 (0.24-1.36)	0.21		
RSPV	0.70 (0.30-1.61)	0.40		
RIPV	0.14 (0.02-1.28)	0.082		
Cor-PA stenosis	3.55 (1.40-8.99)	0.008	3.41 (1.31-8.86)	0.012
Stenosis severity of the Cor-PA				
Normal	1 (Ref)			
Mild	1.86 (0.63-5.50)	0.26		
Moderate	5.11 (1.55-16.81)	0.007		
Severe	4.93 (1.75-13.88)	0.003		
MLD, mm	0.67 (0.48-0.92)	0.013		
RVD, mm	0.78 (0.64-0.96)	0.019	0.79 (0.64-0.98)	0.032

Lesion length, mm	0.98 (0.93-1.03)	0.40
Diameter stenosis, %	1.02 (0.99-1.05)	0.13
FLD, mm	0.79 (0.65-0.97)	0.021
FLD/RVD	0.44 (0.03-7.26)	0.56
Maximal balloon diameter, mm	0.86 (0.67-1.09)	0.20
Maximal balloon length, mm	1.00 (0.93-1.09)	0.92
Maximal balloon pressure, atm	1.14 (0.98-1.34)	0.093
Balloon-to-vessel ratio	6.62 (0.79-55.82)	0.082
Stent diameter	0.79 (0.62-0.99)	0.047
Stent length, mm	0.93 (0.87-0.99)	0.042
Maximal stent pressure, atm	1.13 (0.96-1.33)	0.14
FLD/Stent	0.05 (0.00-1.05)	0.053
Stent-to-vessel ratio	22.62 (0.63-817.65)	0.088
Overlapping stents, n (%)	0.70 (0.16-3.07)	0.64
Pre-PVFG, 0/1/2/3		
0	1 (Ref)	
1	0.70 (0.17-2.85)	0.62
2	0.47 (0.12-1.80)	0.27
Pressure gradient, mmHg		

Pd-pre	0.99 (0.96-1.02)	0.53
Pd-post	0.89 (0.76-1.04)	0.13

483 CI: Confidence interval; OR: Odds ratio. Abbreviations as in Table 2.

484

485 Table 4 Short-term efficacy of percutaneous pulmonary venoplasty in patients with PVS-FM

	Baseline	Follow up	Ν	P Value
Exercise capacity				
6MWD, m	307.6 ± 107.1	326.1 ± 78.2	18	0.28
WHO-FC, I/II/III/IV	0/14/19/2	1/15/18/1	35	0.49
Hemodynamics				
sPAP, mmHg	69.3 ± 22.8	58.9 ± 19.0	23	0.024
dPAP, mmHg	27.0 (23.0, 36.0)	27.0 (17.0, 33.0)	23	0.008
mPAP, mmHg	39.0 (33.0, 52.0)	34.0 (30.0, 44.0)	23	0.016
PAWP, mmHg	7.0 (6.0, 9.3)	8.0 (4.0, 11.0)	23	0.39
mRAP, mmHg	3.0 (2.0, 6.0)	3.0 (2.0, 4.0)	23	0.54
PVR, WU	6.9 (5.3, 10.0)	6.3 (3.9, 9.5)	23	0.32
SvO ₂ , %	62.0 (57.0, 68.0)	66.0 (58.0, 70.0)	23	0.69
CO, L/min	4.3 ± 1.3	4.4 ± 1.2	23	0.69
CI, L/min/m ²	2.7 ± 0.7	2.8 ± 0.7	23	0.57

Echocardiograph	ic
-----------------	----

	LA size, mm	32.2 ± 5.4	32.8 ± 3.8	39	0.44		
	TAPSE, mm	17.3 ± 4.5	19.5 ± 3.9	30	0.016		
	RAA, end-systolic, cm ²	16.2 (14.1, 20.3)	17.0 (14.0, 21.8)	21	0.73		
	RVA, end-diastolic, cm ²	25.1 (16.3, 34.9)	28.5 (19.9, 37.7)	20	0.018		
Others							
	SaO ₂ , %	89.3 ± 4.9	88.1 ± 5.9	38	0.38		
	NT-proBNP, pg/ml	738.0 (203.0, 2678.0)	360.1 (145.3, 1602.5)	41	0.74		
	Refractory pleural effusion, n (%)	35 (81.3)	20 (46.5)	43	< 0.005		
	CRP, mg/L	6.3 (2.5, 29.5)	4.0 (1.4, 16.1)	37	0.054		
	D-Dimer, ug/ml	1.2 ± 0.7	1.3 ± 1.0	36	0.67		

486 Abbreviations as in Table 1.

495 Figure Legends

496 Figure 1. Flowchart of patient enrollment

- 497 Figure 2. Cumulative incidence of ISR
- 498 Kaplan–Meier curve depicting the probability of ISR over a median of 6.6 (3.4-15.7)
- 499 months.

500 Figure 3. ROC analysis for the determination of ISR in the PVS-FM

- 501 (A) RVD had a sensitivity and specificity of 0.84 and 0.38, respectively, for a cutoff
- 502 point of 8.4 mm (AUC, 0.62; 95% CI, 0.52 to 0.71; *P*=0.019) (blue line). (B) Cor-PA
- stenosis had a sensitivity and specificity of 0.89 and 0.69, respectively (AUC, 0.60;
- 504 95% CI, 0.51 to 0.70; P=0.046) (yellow line). (C) Binary logistic regression analysis
- 505 rendered the following formula for the prediction of ISR: Logit (P)=0.614-
- 506 0.236×RVD+1.226×Cor-PA stenosis (AUC, 0.68; 95% CI, 0.59 to 0.77; P<0.001)
- 507 (green line). (D) Kaplan–Meier survival plot comparing freedom from restenosis 508 stratified by RVD. There was a significant difference (P<0.005 for a log-rank test)

between the RVD <8.4 mm (orange solid line) and >8.4 mm (purple dashed line)

510 groups.

509

511 Figure 4. Immediate and short-term efficacy

512 A-C show the immediate effects of the intervention. D-F show the short-term effects 513 of PV intervention alone. When the pre- and postintervention data were compared, 514 there was a significant improvement in MLD, Pd, and PVFG (P<0.001 for all). There 515 was a significant improvement in pleural effusion but no changes in WHO-FC and

516 6MWD after PV intervention compared with baseline (P<0.005, P>0.05, and P>0.05,

517 respectively).

518 Central illustration

- 519 Based on the constructed prediction model, the RVD and stenosis of Cor-PA were
- 520 found to be independently associated with ISR, and their sensitivity and optimal
- 521 cutoff values for the prediction of restenosis are shown in (a) and (b), respectively.
- 522 The risk of ISR significantly increased when PA stenosis occurred; the risk of
- 523 restenosis decreased significantly when the RVD was larger than 8.4 mm.







Figure 4 Immediate and short-term efficacy



Central illustration

Incidence and predictors of ISR following intervention for PVS-FM

